Figures & data
Table 1. Studies assessing the immunological response after HBV vaccination in adults in the HAART era
Table 3. Studies assessing the immunological response after HAV vaccination in adults in the HAART era
Table 2. Key issues in hepatitis B vaccination in adults living with HIV
Table 3. Key issues in hepatitis A vaccination in adults living with HIV
Sasaki Md, Foccacia R, de Messias-Reason IJ. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003;21:4545-9. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005;23:2902-8. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005;41:1045-8. Cornejo-Juarez P, Volkow-Fernandez P, Escobedo-Lopez K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramirez LE. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther 2006;3:9. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 2006;24:7124-8. Ungulkraiwit P, Jongjirawisan Y, Atamasirikul K, Sungkanuparph S. Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients. Southeast Asian J Trop Med Public Health 2007;38:680-5. De Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008;197:292-4. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008;19:600-4. Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis 2008; 12:e77-83. Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, Nardi S, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009;27:17-22. Potsch DV, Oliveira ML, Ginuíno C, Miguel JC, Oliveira SA, Silva EF, et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine 2010;28:1447-50. Psevdos G, Kim JH, Groce V, Sharp V. Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients. AIDS Patient Care STDS 2010;24:403-7. Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, et al. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine 2010;28:5597-604. Pettit NN, DePestel DD, Malani PN, Riddell J 4th. Factors associated with seroconversion after standard dose hepatitis B vaccination and high-dose revaccination among HIV-infected patients. HIV Clin Trials 2010;11:332-9. Overton E, Sungkanuparph S, Klebert M, Royal M, Demarco-Shaw D, Powderly W, et al. GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. Open Virol J 2011;5:109-13. De Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008;197:292-4. Launay O, van der Vliet D, Rosenberg AR, Michel M-L, Piroth L, Rey D, Colin de Verdière N, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011;305:1432-40. Kim JH, Psevdos G, Groce V, Sharp V. Persistence of protective hepatitis B surface antibody titers after successful double-dose hepatitis B virus rescue vaccination in HIV-infected patients. Gut Liver 2012; 6:86-91. Mena G, Llupià A, García-Basteiro AL, Díez C, León A, García F, et al. Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine 2012; 30:3703-9. Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuíno C, et al. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine 2012;30:5973-7. Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: A randomized, controlled trial. PLoS One 2013;8:e80409. Irungu E, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, et al. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. J Infect Dis 2013;207:402-10. Rock C, de Barra E de, Sadlier C, Kelly S, Dowling C, McNally C, et al. Impact of a new vaccine clinic on hepatitis B vaccine completion and immunological response rates in an HIV-positive cohort. J Infect Public Health 2013;6:173-8. Wallace MR, Brandt CJ, Earhart KC, Kuter BJ, Grosso AD, Lakkis H, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004;39:1207-13. Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat 2006;13:81-6. Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS 2005;19:1702-4. Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 2007;14:189-93. Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 2008;49:272-5. Crum-Cianflone NF, Wilkins K, Lee AW, Grosso A, Landrum ML, Weintrob A, et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011;203:1815-23. Kourkounti S, Mavrianou N, Paparizos VA, Kyriakis K, Hatzivassiliou M, Kordosis T, et al. Immune response to hepatitis A vaccination in HIV-infected men in Greece. Int J STD AIDS 2012;23:464-7. Mena G, Llupià A, García-Basteiro AL, Díez C, León A, García F, et al. Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine 2012; 30:3703-9. Tseng YT, Chang SY, Liu WC, Sun HY, Wu CH, Wu PY, et al. Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. Hepatology 2013;57:1734-41. Jimenez HR, Hallit RR, Debari VA, Slim J. Hepatitis A vaccine response in HIV-infected patients: are TWINRIX and HAVRIX interchangeable? Vaccine 2013;31:1328-33. Kourkounti S, Papaizos V, Leuow K, Kordosis T, Antoniou C. Hepatitis A vaccination and immunological parameters in HIV-infected patients. Viral Immunol 2013;26:357-63. Jablonowska E, Kuydowicz J. Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation. Int J STD AIDS 2014;25:745-50.